3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
221
Carcinoma, Non-Small-Cell Lung
218
Prostatic Neoplasms
150
Multiple Myeloma
140
Neoplasms
129
Colorectal Neoplasms
117
Leukemia, Myeloid, Acute
106
Lung Neoplasms
102
Neoplasm Metastasis
95
Squamous Cell Carcinoma of Head and Neck
91
Carcinoma, Hepatocellular
84
Lymphoma
78
Melanoma
77
Triple Negative Breast Neoplasms
71
Pancreatic Neoplasms
71
Ovarian Neoplasms
66
Sarcoma
64
Lymphoma, Large B-Cell, Diffuse
61
Carcinoma, Renal Cell
59
Precursor Cell Lymphoblastic Leukemia-Lymphoma
57
Head and Neck Neoplasms
57
Recurrence
56
Brain Neoplasms
56
Lymphoma, Non-Hodgkin
53
Hematologic Neoplasms
52
Stomach Neoplasms
51
Leukemia, Lymphocytic, Chronic, B-Cell
51
Endometrial Neoplasms
50
Small Cell Lung Carcinoma
48
Rectal Neoplasms
46
Interventions
pembrolizumab
1
Paclitaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Squamous Non-small Cell Lung Cancer
×
90 days
×
Clear all
NCT07221474
2026-05-28
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled